AYTU BIOPHARMA, INC — Revenue by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/bc3db31d-fa98-4c0b-aaca-c11530673175/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $66.4M | 2024-07-01 – 2025-06-30 | evidence 0001437749-25-029723 |
| FY 2024 | $65.2M | 2023-07-01 – 2024-06-30 | evidence 0001437749-25-029723 |
| FY 2023 | $107.4M | 2022-07-01 – 2023-06-30 | evidence 0001558370-23-016393 |
| FY 2022 | $96.7M | 2021-07-01 – 2022-06-30 | evidence 0001558370-22-014652 |
| FY 2021 | $65.6M | 2020-07-01 – 2021-06-30 | evidence 0001558370-21-012825 |
| FY 2020 | $27.6M | 2019-07-01 – 2020-06-30 | evidence 0001558370-21-012825 |
| FY 2019 | $7.3M | 2018-07-01 – 2019-06-30 | evidence 0001654954-19-011147 |
| FY 2018 | $3.7M | 2017-07-01 – 2018-06-30 | evidence 0001654954-19-011147 |
| FY 2017 | $3.2M | 2016-07-01 – 2017-06-30 | evidence 0001213900-18-012209 |
| FY 2016 | $2.6M | 2015-07-01 – 2016-06-30 | evidence 0001144204-16-122393 |
| FY 2015 | $261.8k | 2014-07-01 – 2015-06-30 | evidence 0001193125-15-333046 |
| FY 2014 | $58.9k | 2013-07-01 – 2014-06-30 | evidence 0001193125-15-333046 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
AYTU BIOPHARMA, INC — all facts · Net Income · Operating Income